Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale

Area of Science:

• Neurology
• Clinical Trials
• Ataxia Research

Background:

• Placebo responses in ataxia clinical trials complicate outcome interpretation.
• Genuine treatment effects can be obscured by placebo effects.

Purpose of the Study:

• To analyze placebo group data from past Friedreich Ataxia trials.
• To investigate the nature and influencing factors of placebo responses in Friedreich Ataxia.

Main Methods:

• Analysis of placebo group data from historical Friedreich Ataxia trials.
• Assessment of changes in appendicular and axial function using modified Friedreich Ataxia Rating Scale (mFARS) subscores.
• Evaluation of the impact of testing frequency, interval, and participant age on placebo response.

Main Results:

• Notable placebo responses were observed in appendicular (limb) function subscores of mFARS.
• Minimal changes were detected in axial function subscores.
• Placebo response intensity correlated positively with the number of consecutive tests, shorter testing intervals, and older participant age.

Conclusions:

• Placebo effects in Friedreich Ataxia trials are predominantly observed in appendicular measures.
• The Upright Stability Score (USS), a subscore of mFARS, shows potential as an independent outcome measure due to its distinct response pattern.
• Findings necessitate careful consideration of trial design and endpoint selection to mitigate placebo effect interference.